Literature DB >> 26573875

The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells.

Katja Storch1, Nils Cordes1.   

Abstract

Cyclin-dependent kinase 9 (CDK9), mainly involved in regulation of transcription, has recently been shown to impact on cell cycling and DNA repair. Despite the fact that CDK9 has been proposed as potential cancer target, it remains largely elusive whether CDK9 targeting alters tumor cell radiosensitivity. Five human head and neck squamous cell carcinoma (HNSCC) cell lines (SAS, FaDu, HSC4, Cal33, UTSCC5) as well as SAS cells stably transfected with CDK9-EGFP-N1 plasmid or empty vector controls were used. Upon either CDK9 small interfering RNA knockdown or treatment with a pan-CDK inhibitor (ZK304709), colony formation, DNA double strand breaks (DSBs), apoptosis, cell cycling, and expression and phosphorylation of major cell cycle and DNA damage repair proteins were examined. While CDK9 overexpression mediated radioprotection, CDK9 depletion clearly enhanced the radiosensitivity of HNSCC cells without an induction of apoptosis. While the cell cycle and cell cycle proteins were significantly modulated by CDK9 depletion, no further alterations in these parameters were observed after combined CDK9 knockdown with irradiation. ZK304709 showed concentration-dependent cytotoxicity but failed to radiosensitize HNSCC cells. Our findings suggest a potential role of CDK9 in the radiation response of HNSCC cells. Additional studies are warranted to clarify the usefulness to target CDK9 in the clinic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26573875     DOI: 10.3892/ijo.2015.3246

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.

Authors:  Hee-Joo Choi; Sora Jin; Hani Cho; Hee-Young Won; Hee Woon An; Ga-Young Jeong; Young-Un Park; Hyung-Yong Kim; Mi Kyung Park; Taekwon Son; Kyueng-Whan Min; Ki-Seok Jang; Young-Ha Oh; Jeong-Yeon Lee; Gu Kong
Journal:  EMBO Rep       Date:  2019-08-30       Impact factor: 8.807

2.  BRCA1 recruitment to damaged DNA sites is dependent on CDK9.

Authors:  Thales C Nepomuceno; Vanessa C Fernandes; Thiago T Gomes; Renato S Carvalho; Guilherme Suarez-Kurtz; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cell Cycle       Date:  2017-02-22       Impact factor: 4.534

3.  The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damage.

Authors:  Qian Zhang; Ryan C Riddle; Qian Yang; Clifford R Rosen; Denis C Guttridge; Naomi Dirckx; Marie-Claude Faugere; Charles R Farber; Thomas L Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-21       Impact factor: 11.205

Review 4.  Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Authors:  Steven R Whittaker; Aurélie Mallinger; Paul Workman; Paul A Clarke
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

5.  miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.

Authors:  Chi Pang; Gang Huang; Kaili Luo; Yuying Dong; Fengtian He; Guankui Du; Man Xiao; Wangwei Cai
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

6.  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.

Authors:  Yogesh A Sonawane; Margaret A Taylor; John Victor Napoleon; Sandeep Rana; Jacob I Contreras; Amarnath Natarajan
Journal:  J Med Chem       Date:  2016-06-03       Impact factor: 7.446

7.  CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.

Authors:  Ashley J Schlafstein; Allison E Withers; Soumon Rudra; Diana Danelia; Jeffrey M Switchenko; Donna Mister; Saul Harari; Hui Zhang; Waaqo Daddacha; Shahrzad Ehdaivand; Xiaoxian Li; Mylin A Torres; David S Yu
Journal:  Int J Breast Cancer       Date:  2018-10-14

Review 8.  Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?

Authors:  Christin Riess; Nina Irmscher; Inken Salewski; Daniel Strüder; Carl-Friedrich Classen; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  Cancer Metastasis Rev       Date:  2020-11-08       Impact factor: 9.264

Review 9.  CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents.

Authors:  Abel Tesfaye Anshabo; Robert Milne; Shudong Wang; Hugo Albrecht
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 10.  The Renaissance of Cyclin Dependent Kinase Inhibitors.

Authors:  Tobias Ettl; Daniela Schulz; Richard Josef Bauer
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.